[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NZ274901A - Chewable gelatin capsule for the treatment of gastric reflux or peptic ulceration comprising polymeric material, carbonate or bicarbonate salt and oil or hydrophilic based liquid vehicle - Google Patents

Chewable gelatin capsule for the treatment of gastric reflux or peptic ulceration comprising polymeric material, carbonate or bicarbonate salt and oil or hydrophilic based liquid vehicle

Info

Publication number
NZ274901A
NZ274901A NZ27490194A NZ27490194A NZ274901A NZ 274901 A NZ274901 A NZ 274901A NZ 27490194 A NZ27490194 A NZ 27490194A NZ 27490194 A NZ27490194 A NZ 27490194A NZ 274901 A NZ274901 A NZ 274901A
Authority
NZ
New Zealand
Prior art keywords
carbonate
pharmaceutical product
product according
oil
aluminium
Prior art date
Application number
NZ27490194A
Inventor
Keith Sugden
Keith Graeme Hutchinson
Original Assignee
Reckitt & Colmann Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939322314A external-priority patent/GB9322314D0/en
Application filed by Reckitt & Colmann Prod Ltd filed Critical Reckitt & Colmann Prod Ltd
Publication of NZ274901A publication Critical patent/NZ274901A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

New Zealand No. 274901 International No. PCT/GB94/02380 Priority Date{3): ComptoJe SpAoificfttion Fiiod: m | Pucrficatkiri Dart»: P.O. Journal Mo: .. mi COMPLETE SPECIFICATION NEW ZEALAND PATENTS ACT 1953 Title of Invention: Gelatin capsule fill able to foam 2RW, United Kingdom , ck PRODUCTS LIMITED, of One Burlinc • | c\ $"£> Lane, London W4 274901 Gelatln capsule fill able to foam This invention relates to pharmaceutical products and in particular to compositions for the treatment of reflux oesophagitis, gastritis or peptic ulceration.
Reflux oesophagitis occurs when small amounts of gastric juice, food and/or bile acids pass into the lower part of the oesophagus and cause oesophageal inflamination accompanied by pain which may manifest itself in the form of heartburn.
One approach to the problem of reflux oesophagitis comprises the administration of a preparation which on contact with gastric acid generates a carbonated gelatinous foam or raft which floats on the stomach contents. When reflux occurs it is this raft which precedes the stomach contents into the oesophagus thus protecting the mucosa from further irritation. Known preparations of this type included solid preparation in the form of powders or tablets containing alginic acid, sodium bicarbonate and antacid materials or liquid preparations containing sodium alginate, sodium bicarbonate and calcium carbonate marketed under the name GAVISCON (TM Reckitt & Colman Products Ltd). In our British Patent No. 1524740 we describe such liquid preparations. In our corresponding German Patent No 2738014 C2 we describe a penetration test used for evaluating raft rigidity. The procedure described is based SUBSTITUTE SHEET (RULE 26) on ASTM D217-68 "Standard Method for Cone Penetration of Lubricating Grease*. In the method described in the patent a lightweight cone assembly of a penetrometer is released and allowed to penetrate into the raft, the depth of penetration being measured. ;In our US Patent No. 4172120 we describe a preparation including cholestyramine which is retained in the stomach for a prolonged period of time and is therefore more effective in binding duodenally reflusced bile. This preparation includes alginic acid and/or sodium alginate together with sodium bicarbonate which on being swallowed react with gastric acid to form a carbonated raft which holds the choles try amine sufficiently loosely that it is able to absorb bile acid in the stomach. ;The carbonated alginic acid raft type of product is further exemplified by ALGICON (Rhone-Poulenc Rorer) described in European Patent No. 0179858 B1 as containing magnesium alginate, potassium bicarbonate, magnesium carbonate and as antacid materials aluminium hydroxide/magnesium carbonate co-dried gel. ;According to the present invention there is provided a pharmaceutical product for the treatment of reflux oesophagitis, gastritis or peptic ulceration in the form of a chewable soft gelatin capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 PCT/GB94/02380 ;-3- ;pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-basea or hydrophilic based liquid vehicle; wherein on oral ingestion the gelatin capsule shell ruptures and the fill reacts with 5 the acid contents of the stomach thereby producing a carbonated floating gelatinous raft of such rigidity that in the penetration test as hereinafter defined there is not complete penetration. ;By complete penetration we mean that the cone of the 10 penetrometer passes completely through the raft. ;Preferably the polymeric material is the sodium, potassium, ammonium, magnesium or calcium salt of alginic acid or the propylene glycol esters or mixtures thereof. ;He have shown that when the polymeric material is 15 alginic acid or a salt or ester thereof rafts of improved strength are obtained if the composition includes a source of divalent calcium or trivalent aluminium ion which act as cross-linking agents. Suitable sources of calcium ions are those derived from the carbonate, lactate, chloride, 20 gluconate, phosphate, hydrogen phosphate, sulphate, tartrate or citrate salts. Suitable sources of aluminium ions are those derived from the carbonate, lactate, glycinate or phosphate salts or from aluminium magnesium carbonate hydroxide, magaldrate, aluminium sodium carbonate hydroxide 25 or aluminium sodium silicate. Conveniently the relative ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 ;PCT/GB94/02380 ;-4- ;quantities by weight of the calcium salt or aluminium compound to the alginic acid or alginate calculated as ions are 4 to 120 Ca2+ to 500 alginate" or 2 to 80 Al3+ to 500 alginate" respectively. ;Suitable carbonate or bicarbonate salts are potassium carbonate or bicarbonate, sodium carbonate or bicarbonate, calcium carbonate, sodium glycine carbonate, magnesium carbonate or aluminium carbonate. The carbonate or bicarbonate salt is present in an amount so as to provide an adequate volume of gas (carbon dioxide) to float the gel produced when the polymeric material contacts the gastric acid in the stomach. Preferably the relative quantities by weight of polymeric material to the carbonate or bicarbonate calculated as ions is 35 to 300 CO32" or HCO3" to 500 polymeric material. ;It will be understood that the rigidity and thickness of the carbonated raft formed on contact with the gastric acid will depend upon the ratio of carbonate or bicarbonate to the polymeric material and upon the grade of the polymeric material. ;Suitable oil-based liquid vehicles are natural oils such as soya bean oil, fractionated coconut oil, mineral oils, triacetin, ethyl oleate, hydrogenated natural oil and mixtures thereof. ;SUBSTITUTE SHEET (RULE 26) ;27 4 9 0 1 ;-5- ;/ ;Suitable hydrophilic based liquid vehicles are polyethylene glycols (PEG'S) particularly PEG 400 and PEG 600, glycofvirol, polyglycerols, propylene glycol, ;Transcutol, polysorbate and propylene carbonate and mixtures 5 thereof. ;Also described but not claimed herein is a method of treating reflux oesophagitis, gastritis or peptic ulceration which comprises administration of an effective amount of a product which is capable of forming a floating gelatinous raft when contacted 10 with the acid contents of the stomach said raft being of such rigidity that in the penetration test as hereinafter defined there is not complete penetration and said product being in the form of a chewable soft gelatin capsule with a fill comprising (a) polymeric material selected from alginic 15 acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle. ;The gelatin capsules may be simultaneously formed and filled using conventional methods and apparatus such as 20 disclosed, for example, in an article by H. Seager in Pharmaceutical Technology September 1985. Thus all the ingredients of the fill material including the liquid vehicle are mixed together, with heating if necessary, until the desired consistency for filling and the desired ;WO 95/11668 ;PCT/GB94/02380 ;-6- ;uniformity is obtained. The encapsulation machine is suitably an R P Scherer encapsulation machine. ;In order to facilitate the even dispersion of the solid components of the fill in the liquid vehicle a surfactant 5 may be included in the fill. ;In the fill the polymeric materials will have a thickening effect upon the liquid fill. This thickening effect may be further increased if so desired by the inclusion of a thickening agent such as hydrogenated 10 vegetable oils, glyceryl monostearate, glyceryl xnonopaImitate, beeswax (or other high melting point fat or wax) or a dispersed thickener such as colloidal silicon dioxide. For hydrophilic vehicles, a suitable thickening agent may be one or more high molecular weight PEG's." IS The capsules will be suitably shaped and sized so as to be readily ingestible by a person following chewing. ;Sodium Bicarbonate BP ;100 mg ;Calcium Carbonate ;30 mg ;25 ;Fractionated Coconut Oil BP ;600 mg ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 ;PCT/GB94/02380 ;10 ;15 ;20 ;-7- ;Lecithin ;Colloidal Silicon Dioxide Sorbitan Fatty Acid Esters Polysorbate 80 BP Flavouring, colouring, sweetener ;12 mg 34 mg 34 mg 20 mg 80 mg ;1410 mg ;Example 2 ;Capsules were prepared as in Example 1 except that the amount of calcium carbonate in the fill materials was increased to 100 mg. ;Example 3 ;Capsules were prepared as in Example 1 having the following fill: ;Quantity/Capsule t ;Sodium Alginate 500 mg ;Xanthan Gum 100 mg ;Sodium Bicarbonate Calcium Carbonate Aerosil ;Flavour, Sweetener Soya Bean Oil ;100 mg 100 mg 35 mg qs qs ad ;1500 mg ;25 Example 4 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 PCT/GB94/02380 ;-8- ;Capsules were prepared as in Example 1 having the following fill: ;Quantity/Capsule ;Alginic Acid ;500 ;mg ;Carrageenan ;100 ;mg ;Sodium Carbonate ;100 ;mg ;Calcium Chloride ;100 ;mg ;Aerosil ;35 ;mg ;Polysorbate 80 ;20 ;mg ;Flavour, Sweetener qs ;Fractionated Coconut Oil qs ad ;1500 mg ;Example ? ;15 Capsules were prepared as in Example l having the following fill: ;Quantity/Capsule ;Magnesium Alginate 500 mg ;Gellan Gum 50 mg ;20 Magaldrate 200 mg ;Sodium Bicarbonate 150 mg ;Glyceryl Mono-Stearate 100 mg ;Polysorbate 80 20 mg ;Flavour, Sweetener qs ;25 Fractionated Coconut Oil qs ad ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 ;PCT/GB94/02380 ;9- ;1600 mg in Example l having the ;Quantity/Capsule 300 mg 300 mg 150 mg 150 mg 150 mg 15 mg qs qs ad ;1550 mg Raft Penetration Test The rigidity of the rafts produced by the products of the invention are assessed by a cone penetration test adapted from ASTM D217-68. This method had been previously described for the determination of alginate raft rigidity in our German Patent No DE 273801 C2. In this patent we used a metal cone assembly of weight 26.Og (cf a weight of 150.Og of ASTM D217-68) as shown in Fig 1. ;Preparation of raft samples ;Example 6 ;Capsules were prepared as following fill: ;Alginic Acid Pectin ;Calcium Carbonate Sodium Bicarbonate Hydrogenated Vegetable Oil Lecithin ;Flavour, Sweetener Arachis Oil ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 PCT/GB94/02380 ;-10- ;The raft was prepared as follows: a bulk sample was prepared sufficient for 6 rafts. ;The appropriate amount of product (equivalent to 6 doses of lq of polymeric material) was weighed and added to 5 a 250ml tall-form beaker (height 120mm & diameter 60mm) previously weighed. A volume of 120ml of deionised water was added and the mixture homogenized for 5 minutes using the Silverson Model L4R homogenizer with a Turbular Unit 1" in diameter and a square hole high shear screen. The speed 10 of the homogenizer was set at speed 4 / 5000-5200 rpm. In the case of Liquid Gaviscon and Algicon Mint, 120ml of the product was taken and added to a 250ml tall-form beaker. A volume of 120ml of deionized water was added and the mixture homogenized for 5 minutes as before. ;IS After homogenization, a quantity of homogenized mixture equivalent to lg of polymeric material was added to 150mls 0.1M HCl in a 250ml low-form beaker (height 94mm & diameter 67nun) preheated to 37#C, using a 50ml Plastipak syringe with 60ml scale and lok tip. The raft was allowed to stand for 20 30 minutes. After that time, the raft depth was measured and the cone penetration test carried out. ;Description of the method ;The Cone Penetration test was carried out using a Penetrometer (Stanhope-Seta, Surrey England) fitted with the 25 cone arrangement described above of weight 26.Og. The tip ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 PCT/GB94/02380 ;-11- ;of the cone was brought carefully into contact with the upper surface of the raft, the dial micrometer arm was brought into contact with the upper surface of the cone assembly, and the dial micrometer was zeroed. The spring 5 loaded release button was depressed for approximately one second, and the cone assembly was allowed to sink into the raft. The centre knob on the dial micrometer was turned to bring the micrometer arm again into full contact with the upper surface of the cone assembly. The depth of 10 penetration was recorded, this being inversely proportional to the rigidity of the raft. The mean of 5 raft evaluations was calculated. ;Experimental Results ;The rigidity of the rafts produced by the products of IS Examples 1 and 2 were assessed by the above method. ;Tests were also carried out on two comparative Examples (a) Liquid Gaviscon (Reckitt & Colman Products Ltd) containing sodium alginate 500 mg, sodium bicarbonate 267 mg, calcium carbonate 160 mg per 10 ml and (b) Algicon 20 suspension (Rhone-Poulenc Rorer) containing magnesium alginate 250 mg, aluminium hydroxide/magnesium carbonate co-dried gel 140 mg, magnesium carbonate 175 mg, potassium bicarbonate 50 mg per 5 ml. ;The results obtained are set out in the Table below. ;25 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/11668 ;PCT/GB94/02380 ;-12-2&1LE ;Product ;Raft Depth (mm) ;Penetration Depth (mm) ;Penetration (*) Example 1 34 33 34 31 Mean = 33 22.1 24.0 29.2 12.1 Mean = 22.08 65.00 75.45 85.88 39.03 Mean = 66.34 Example 2 34 34 30 33 33 Mean «■ 32.8 .5 7.7 9.3 9.8 .6 Mean =9.58 .88 22.65 31.00 29.70 32.12 Mean « 29.27 Liquid Gaviscon 37 40 42 40 40.5 Mean = 39.9 9.7 9.5 12.8 8.7 11.1 Mean = 10.36 26.22 23.75 30.48 21.75 27.41 Mean - 25.92 Algicon 34 36 32 34 36.5 Mean - 16.0 Complete M If n i« Mean = Complete 100 100 100 100 100 Mean « 100 In the case of Algicon the cone of the penetrometer passed completely through the rafts.
SUBSTITUTE SHEET (RULE 26) 2.7 4 9 0 1

Claims (2)

  1. WHAT WE CLAIM IS: 1. A pharmaceutical product for the treatment of reflux oesophagitis, gastritis or peptic ulceration in the form of 5 a chevable soft gelatin capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle; wherein on oral ingestion 10 the gelatin capsule shell ruptures and the fill reacts with the acid contents of the stomach thereby producing a carbonated floating gelatinous raft of such rigidity that in the penetration test as hereinbefore defined there is not complete penetration.
  2. 2. A pharmaceutical product according to Claim 1 wherein the polymeric material is the sodium, potassium, ammonium, magnesium or calcium salt of alginic acid or the propylene glycol ester or a mixture thereof. 4. A pharmaceutical product according to Claim 3 wherein 25 the calcium ion is derived from the carbonate, 15 20 3. A pharmaceutical product according to Claim 2 which includes a calcium or aluminium cross-linking ion. 274 90 1 -14- chloride, gluconate, phosphate, hydrogen phosphate, sulphate, tartrate or citrate salt. 5. A pharmaceutical product according to Claim 3 wherein 5 the aluminium ion is derived from the carbonate, lactate, glycinate or phosphate salt or from aluminium magnesium carbonate hydroxide, magaldrate, aluminium sodium carbonate hydroxide or aluminium sodium silicate. 10 6. A pharmaceutical product according to Claim 4 wherein the relative quantities by weight of the calcium salt to the alginic acid or alginate calculated as ions is 4 to 120 Ca2+ to 500 alginate-. 15 7. A pharmaceutical product according to Claim 5 wherein the relative quantities by weight of the aluminium compound to the alginic acid or alginate calculated as ions is 2 to 80 Al3+ to 500 alginate". 20 8. A pharmaceutical product according to any one of the preceding Claims wherein the carbonate or bicarbonate salt is potassium carbonate or bicarbonate, sodium carbonate or bicarbonate, calcium carbonate, sodium glycine carbonate, magnesium carbonats or aluminium carbonate. *27 4 9 0 1 -15- 9. A pharmaceutical product according to any one of the preceding Claims wherein the relative quantities by weight of carbonate or bicarbonate to the polymeric material calculated as ions is 35 to 300 CC^2- or HCO3" to 500 5 polymeric material. 10. A pharmaceutical product according to any one of the preceding Claims wherein the oil-based liquid vehicle is a natural oil such as soya bean oil, fractionated coconut oil, 10 mineral oil, triacetin, ethyl oleatef a hydrogenated natural oil or mixture thereof. 11. A pharmaceutical product according to any one of Claims 1 to 9 wherein the hydrophilic based liquid vehicle is a IS polyethylene glycol (PEG'S) particularly PEG 400 and PEG 600, glycofurol, polyglycerols, propylene glycol, transcutol, polysorbate, propylene carbonate or mixtures thereof. 20 12. A pharmaceutical product according to any one of the preceding Claims wherein the fill includes a thickening agent. 13. A pharmaceutical product according to any one of the 25 preceding Claims wherein the fill includes a surfactant. 14. A pharmaceutical product as defined in claim 1 for the treatment of reflux oesophagitis, gastritis or peptic ulceration in the form of a chewable soft gelatin capsule with a fill substantia^i^fe^s herein described with reference to any example thera*»f^aEndr or without reference to the accompanying drawi^iC itchi4j^k fcl ^<^\JvoJ.ucU Liu*L,lrJ snts PA Hi Per (J//>
NZ27490194A 1993-10-29 1994-10-28 Chewable gelatin capsule for the treatment of gastric reflux or peptic ulceration comprising polymeric material, carbonate or bicarbonate salt and oil or hydrophilic based liquid vehicle NZ274901A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939322314A GB9322314D0 (en) 1993-10-29 1993-10-29 Foam generating capsules
GB9411350A GB2283171B (en) 1993-10-29 1994-06-07 Pharmaceutical products

Publications (1)

Publication Number Publication Date
NZ274901A true NZ274901A (en) 1997-03-24

Family

ID=26303761

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ27490194A NZ274901A (en) 1993-10-29 1994-10-28 Chewable gelatin capsule for the treatment of gastric reflux or peptic ulceration comprising polymeric material, carbonate or bicarbonate salt and oil or hydrophilic based liquid vehicle

Country Status (9)

Country Link
EP (1) EP0725626A1 (en)
JP (1) JPH09504286A (en)
CN (1) CN1133558A (en)
AU (1) AU8000494A (en)
BR (1) BR9407916A (en)
CA (1) CA2174777A1 (en)
NO (1) NO961638D0 (en)
NZ (1) NZ274901A (en)
WO (1) WO1995011668A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3959192B2 (en) * 1998-12-03 2007-08-15 株式会社大塚製薬工場 Tube feeding food
SE0103722D0 (en) * 2001-10-30 2001-10-30 Astrazeneca Ab Novel formulation
GB2384986B (en) * 2002-02-12 2004-01-07 Reckitt Benckiser Healthcare Compositions for the treatment of disorders of the upper gastrointestinal tract
EP1951208A2 (en) * 2005-10-26 2008-08-06 Banner Pharmacaps Inc. Lipophilic vehicle-based dual controlled release matrix system as capsule fill
KR100919508B1 (en) * 2007-08-14 2009-09-28 강원대학교산학협력단 Alginate particle containing calcium carbonate in matrix and the method for production of the said alginate particle
GB0814376D0 (en) * 2008-08-06 2008-09-10 Reckitt Benckiser Healthcare Formulation
EP2560732A2 (en) * 2010-04-23 2013-02-27 S-Biotek Holding ApS A solid pharmaceutical composition for neutralizing stomach acid
ITUB20156821A1 (en) 2015-12-09 2017-06-09 Altergon Sa JELLY CAPSULES SPRINGS RELEASE INDEPENDENT pH
FR3071728B1 (en) 2017-09-29 2019-09-27 Laboratoires Arkopharma COMPOSITION SUITABLE FOR FORMING A GASTRIC GEL RAFT
IL312094A (en) * 2018-03-02 2024-06-01 Pharagen Llc Acid reflux treatment formulations that include sodium alginate
CN110353271B (en) * 2019-06-13 2022-07-22 陕西科技大学 Special medical food thickening component for inhibiting esophagus reflux and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
CH652025A5 (en) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmaceutical preparation.
CA1327748C (en) * 1988-09-20 1994-03-15 Christopher William Quirk Pharmaceutical composition containing ranitidine and alginic acid

Also Published As

Publication number Publication date
CN1133558A (en) 1996-10-16
WO1995011668A1 (en) 1995-05-04
CA2174777A1 (en) 1995-05-04
AU8000494A (en) 1995-05-22
JPH09504286A (en) 1997-04-28
NO961638L (en) 1996-04-24
BR9407916A (en) 1996-11-26
NO961638D0 (en) 1996-04-24
EP0725626A1 (en) 1996-08-14

Similar Documents

Publication Publication Date Title
CA1267090A (en) Aerosol foam
NZ274901A (en) Chewable gelatin capsule for the treatment of gastric reflux or peptic ulceration comprising polymeric material, carbonate or bicarbonate salt and oil or hydrophilic based liquid vehicle
EP1978943B1 (en) Chewable capsules
AU594148B2 (en) Gelatin-encapsulated controlled-release composition
US9452135B2 (en) Gelling agent-based dosage form
GB2283171A (en) Pharmaceutical product for treatment of reflux oesophagitis,gastritis or peptic ulceration
WO1988007862A1 (en) An antacid composition
AU2022256816A1 (en) Supported nicotine composition
US5888540A (en) Pharmaceutical products
AU669067B2 (en) Novel rafting antacid formulation
AU692483B2 (en) Gelatin capsule fill able to foam
CA1116084A (en) Negative contrast agent
EA047934B1 (en) NEW COMBINATIONS AND COMPOSITIONS OF SUCRALFATE IN ALGINATE AND ITS USE IN THERAPY
IE913309A1 (en) Effective solid non-lozenge anti-acid/anti-gas medicament